News
-
-
PRESS RELEASE
Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC
Oxurion NV received a transparency notification from Atlas Special Opportunities II, LLC regarding changes in shareholding. The company specializes in acquiring stakes in European pharmaceutical subcontractors. Risks associated with forward-looking statements and planned investments in digital assets are highlighted -
-
-
-
-
-
-
-
PRESS RELEASE
Axiodis CRO, the French subsidiary of the Oxurion Group, announces a dual AI-driven strategic initiative to transform clinical trials
Axiodis CRO, a subsidiary of Oxurion NV, leverages AI to enhance clinical trials with digital twins for disease simulation and AI modules integrated into Exagis eCRF solution for improved data quality and workflow efficiency